background
procoagul
membran
microvesicl
mv
deriv
platelet
leukocyt
shed
circul
follow
receptormedi
activ
cellcel
interact
apoptosi
platelet
sentinel
marker
tolllik
receptor
activ
experi
design
evalu
time
cours
mechan
direct
interact
platelet
leukocyt
follow
acut
activ
bacteri
lipopolysaccharid
lp
methodologyprincip
find
blood
agematch
male
femal
wild
type
wt
gene
delet
mice
incub
ultrapur
e
coli
lp
ngml
one
hour
design
period
leukocyt
antigen
posit
platelet
platelet
antigen
posit
leukocyt
cellderiv
mv
quantifi
flow
cytometri
number
plateletor
leukocytederiv
mv
increas
within
one
hour
follow
vitro
exposur
blood
lp
howev
lp
stimul
number
platelet
stain
posit
plateletand
leukocytespecif
antigen
increas
blood
deriv
wt
mice
effect
block
inhibit
signal
mediat
trif
seven
day
singl
intraven
inject
lp
ngmous
nggm
bodi
wt
wt
mice
none
platelet
stain
leukocyt
antigen
howev
granulocyt
monocyt
apoptot
bodi
stain
posit
platelet
antigen
conclusionssignific
within
one
hour
exposur
lp
leukocyt
exchang
surfac
antigen
platelet
activ
vivo
leukocyt
express
platelet
antigen
retain
singl
exposur
lp
follow
turn
platelet
pool
acut
express
leukocyt
antigen
platelet
within
one
hour
exposur
lp
sustain
express
platelet
antigen
leukocyt
follow
singl
acut
exposur
lp
vivo
explain
part
associ
platelet
leukocyt
respons
bacteri
infect
chang
thrombot
propens
blood
acut
chronic
infect
especi
induc
gramneg
bacteria
associ
increas
risk
thrombosi
atherosclerot
diseas
littl
known
underli
cellular
mechan
respons
risk
lipopolysaccharid
lp
compon
cell
wall
gramneg
bacteria
antigen
initi
inflamm
innat
immun
respons
interact
tolllik
receptor
express
surfac
cell
includ
leukocyt
platelet
physiolog
condit
platelet
leukocyt
circul
quiescent
state
interact
howev
activ
pathophysiolog
condit
associ
infect
platelet
chang
shape
secret
prothrombogen
inflammatori
cellular
adhes
molecul
alphaand
densegranul
caus
platelet
adher
leukocyt
andor
vascular
endothelium
physiolog
consequ
stimuli
associ
infect
like
lp
stimul
acut
sustain
exampl
halflif
platelet
shorten
activ
state
newli
form
platelet
bone
marrow
megakaryocyt
increas
within
seven
day
follow
singl
acut
intraven
inject
lp
mice
howev
cellular
event
specif
occur
among
blood
element
contribut
shorten
halflif
increas
activ
state
platelet
remain
clarifi
one
mechan
offer
explain
infect
contribut
onset
progress
cardiovascular
diseas
increas
product
proinflammatori
cytokin
howev
explan
address
product
inflammatori
cytokin
might
proceed
ident
cell
type
target
lp
stimul
platelet
may
repres
one
first
blood
born
element
react
lp
stimul
chang
platelet
reactiv
via
seem
occur
prior
sustain
chang
circul
level
cytokin
altern
compar
activ
leukocyt
well
platelet
result
format
cellderiv
microvesicl
mv
may
contribut
increas
thrombogen
propens
blood
proinflammatori
immun
process
thu
cardiovascular
risk
clarifi
interact
blood
element
platelet
leukocyt
set
activ
might
provid
insight
infect
initi
facilit
progress
cardiovascular
diseas
mv
cell
membranederiv
vesicl
rang
size
micron
diamet
shed
respons
cellular
activ
cellcel
interact
apoptosi
cellderiv
vesicl
interfac
activ
cellular
compon
blood
vascular
wall
solubl
compon
blood
associ
immun
includ
respons
infect
exampl
phosphatidylserin
ps
surfac
mv
provid
catalyt
site
prothrombinas
complex
gener
thrombin
need
convers
fibrinogen
fibrin
format
clot
furthermor
exposur
dilut
blood
lp
vitro
increas
product
plateletderiv
well
tissu
factor
posit
mv
within
hour
experi
provid
evid
lp
modul
platelet
activ
provid
insight
interact
platelet
blood
element
within
earliest
stage
activ
especi
time
point
prior
period
measur
chang
circul
cytokin
observ
vivo
therefor
present
studi
design
test
hypothesi
acut
exposur
sentinel
dose
lp
would
induc
mv
product
exchang
specif
protein
receptor
platelet
leukocyt
via
activ
mv
transport
biolog
activ
cell
content
includ
cell
surfac
receptor
among
cell
identifi
use
antibodi
specif
cell
antigen
ie
plateletor
leukocytespecif
antigen
respect
mv
deriv
platelet
andor
leukocyt
distinguish
cell
specif
fluorescein
conjug
antigen
stain
use
calibr
flow
cytometri
four
eight
month
old
male
femal
mice
wild
type
wt
mice
homozyg
delet
obtain
jackson
laboratori
bar
harbor
main
mice
express
mutat
origin
describ
strain
mice
sex
age
use
randomli
variou
protocol
mice
hous
temperaturecontrol
environ
rel
humid
lightdark
cycl
fed
standard
chow
experi
approv
institut
anim
care
use
committe
mayo
clinic
rochest
mn
ultrapur
ecoli
lipopolysaccharid
lp
ligand
product
number
tlrlpelp
pepinhmyd
product
number
tlrlpimyd
pepinhtrif
product
number
tlrlpitrif
inhibitori
peptid
invivogen
san
diego
ca
prepar
suggest
supplier
mous
thrombin
bovin
serum
albumin
purchas
sigma
chemic
co
st
loui
mo
usa
cellular
origin
antigen
determin
use
platelet
rat
antimous
antibodi
total
leukocyt
rat
antimous
antibodi
membran
specif
fluorescein
conjug
phycoerythrin
pe
fluorescein
isothiocyan
fitc
antibodi
flow
cytometri
peor
fitcconjug
annexinv
match
isotyp
control
antibodi
purchas
bd
pharmingen
intern
san
diego
ca
reagent
solvent
use
studi
analyt
reagent
grade
blood
collect
retroorbit
sinu
plexu
mlmous
wild
type
mice
silicon
capillari
tube
coat
hirudin
thrombin
inhibitor
soybean
trypsin
inhibitor
sti
factor
xa
inhibitor
ml
polypropylen
tube
contain
ml
mm
hirudin
mm
sti
vitro
experi
anticoagul
blood
aliquot
pair
tube
within
min
collect
measur
vehicletr
control
tube
lpstreat
tube
could
analyz
mous
time
point
vehicl
salin
lp
ngml
ad
one
pair
aliquot
blood
design
time
point
minut
addit
vehicl
lp
ml
whole
blood
aliquot
dilut
ml
hepe
hank
buffer
mm
nacl
mm
kcl
mm
cacl
mm
mgso
mm
na
hpo
mm
hepe
ph
mgml
albumin
mm
sti
stain
platelet
posit
leukocyt
antigen
leukocyt
posit
platelet
antigen
remain
blood
use
prepar
platelet
free
plasma
pfp
mv
analysi
vivo
experi
male
mice
month
age
receiv
singl
inject
lp
ngmous
nggm
bodi
weight
tail
vein
seven
day
inject
blood
collect
describ
analysi
platelet
antigen
posit
leukocyt
subpopul
flow
cytometri
trigger
total
leukocyt
marker
allophycocyanin
posit
event
contain
granulocyt
monocyt
lymphocyt
apoptot
bodi
separ
light
forward
side
scatter
blot
analysi
gate
subtyp
leukocyt
base
size
gate
verifi
use
cell
specif
antibodi
granulocyt
monocyt
tlymphocyt
blymphocyt
differenti
leukocyt
popul
subject
twocolor
analysi
differenti
leukocyt
posit
phosphatidylserin
platelet
antigen
annexinvfitc
vs
leukocyt
neg
phosphatidylserin
platelet
antigen
percentag
posit
event
calcul
set
threshold
isotyp
control
antibodi
blood
sampl
mous
divid
two
ml
aliquot
one
dilut
ml
salin
control
ml
salin
contain
lp
ngml
final
concentr
sampl
incub
timepoint
prior
lp
vehicl
min
ml
aliquot
remov
sampl
dilut
ml
paraformaldehyd
incub
addit
min
sampl
dilut
ml
pb
mm
pore
membranefilt
centrifug
min
supern
contain
platelet
remov
place
new
vial
use
imag
analysi
aliquot
platelet
suspens
dilut
pb
ml
drop
place
glass
slide
coverslip
seal
glue
platelet
imag
darkfield
mode
use
light
microscop
olympu
oilimmers
len
coupl
cytoviva
illumin
system
cytoviva
inc
auburn
al
scan
corner
coverslip
platelet
field
count
total
platelet
categor
accord
shape
morpholog
discoid
irregular
flatten
pseudopodia
whether
exhibit
membran
granul
aggreg
aggreg
count
number
platelet
categori
express
percentag
total
platelet
count
dilut
whole
blood
ml
incub
peconjug
plateletand
leukocytespecif
antibodi
respect
separ
annexin
vfitc
bind
phosphatidylserin
min
paraformaldehyd
ml
ad
match
fluorescein
conjug
isotyp
control
antibodi
use
simultan
stain
set
threshold
exclud
nonspecif
bind
interact
cell
platelet
leukocyt
cellderiv
mv
ps
express
platelet
leukocyt
analyz
flow
cytometri
facscalibur
tm
facscanto
tm
bd
bioscienc
san
jose
ca
platelet
identifi
forward
side
scatter
fluorescein
conjug
antibodi
event
gate
sampl
respect
figur
buffer
antibodi
filter
twice
mm
membran
millipor
filter
mv
analysi
platelet
free
plasma
pfp
prepar
doubl
centrifug
min
pfp
dilut
ml
ml
hepeshank
buffer
incub
ml
fitcconjug
annexinv
peconjug
antibodi
min
dark
time
ml
hank
balanc
salt
buffer
ph
mm
cacl
ad
match
isotyp
control
antibodi
use
set
threshold
exclud
nonspecif
bind
mv
quantifi
base
count
calibr
bead
trucount
tm
bead
ad
immedi
sampl
prior
analysi
flow
cytometri
facscanto
tm
bd
bioscienc
san
jose
ca
previous
describ
studi
mv
defin
event
mm
diamet
use
size
calibr
bead
posit
annexinv
plateletand
leukocytespecif
marker
analysi
intracellular
signal
pathway
lp
stimul
signal
analyz
introduc
trif
inhibitori
peptid
describ
studi
anticoagul
blood
wt
mice
aliquot
six
tube
treat
pepinhcontrol
vehicl
pepinhmyd
mm
inhibitori
peptid
bind
block
stimul
signal
andor
pepinhtrif
mm
bind
trif
block
stimul
trif
signal
alon
combin
min
either
salin
lp
ngml
ad
one
hour
time
aliquot
dilut
analysi
flow
cytometri
measur
cellular
origin
mv
platelet
posit
leukocyt
antigen
leukocyt
posit
platelet
antigen
data
present
percentag
fold
increas
pair
vehicl
lp
treat
blood
sampl
time
point
data
present
mean
sem
n
number
anim
use
experi
statist
signific
evalu
pair
unpair
twotail
student
ttest
statist
signific
accept
prior
addit
lp
platelet
wt
mice
discoid
form
aggreg
extend
psuedopodia
figur
surfac
express
ps
platelet
leukocyt
similar
wt
mice
within
group
mice
express
ps
significantli
lower
leukocyt
platelet
tabl
first
hour
incub
blood
lp
platelet
wt
mice
underw
shape
chang
extend
pseudopodia
form
aggreg
figur
within
first
hour
neither
surfac
express
ps
either
platelet
leukocyt
number
plateletor
leukocytederiv
mv
chang
significantli
wt
mice
mice
tabl
howev
number
platelet
posit
leukocytespecif
antigen
defin
plateletg
flow
cytomet
figur
increas
significantli
timedepend
manner
blood
wt
mice
mice
figur
use
total
leukocyt
specif
antibodi
defin
total
leukocyt
number
leukocyt
posit
plateletspecif
antigen
increas
significantli
either
wt
mice
figur
blood
wt
mice
percentag
platelet
posit
leukocyt
antigen
reduc
significantli
extent
trif
figur
combin
trif
reduc
percentag
aggreg
greater
extent
either
alon
seven
day
follow
singl
intraven
inject
sentinel
dose
lp
nggm
bodi
weight
ngmous
none
platelet
posit
leukocyt
antigen
contrari
compar
leukocyt
obtain
anim
treat
vehicl
week
lp
inject
mous
granulocyt
monocyt
significantli
posit
platelet
antigen
seven
day
singl
lp
inject
figur
apoptot
bodi
also
stain
posit
platelet
antigen
figur
understand
infect
alter
cellcel
interact
releas
mv
specif
blood
born
element
may
help
identifi
new
target
reduc
cardiovascularthrombot
risk
infect
studi
demonstr
acut
immedi
interact
platelet
leukocyt
incub
whole
blood
sentinel
dose
lp
signal
exchang
antigen
associ
specif
cellderiv
mv
among
cell
mechan
transfer
signal
molecul
specif
cell
exampl
mv
deriv
neutrophil
induc
platelet
activ
bind
platelet
glycoprotein
via
activ
b
mv
plateletderiv
mv
mediat
leukocyteleukocyt
aggreg
activ
leukocyt
phagocyt
properti
amplifi
leukocytemedi
tissu
injuri
thrombot
inflammatori
disord
result
present
studi
demonstr
number
platelet
posit
leukocyt
antigen
increas
within
min
exposur
lp
increas
accompani
increas
express
ps
cell
mv
surfac
express
leukocyt
antigen
platelet
defin
use
platelet
size
gate
platelet
specif
marker
flow
cytometri
larger
leukocyt
would
exclud
therefor
leukocyt
antigen
may
repres
membran
exchang
plateletleukocyt
adhes
adhes
leukocytederiv
mv
platelet
halflif
whole
plateletleukocyt
aggreg
may
shorter
therefor
determin
whole
plateletleukocyt
aggreg
studi
agonist
bind
dimer
undergo
conform
chang
requir
recruit
signal
molecul
adaptor
molecul
myeloid
differenti
protein
receptor
figur
repres
darkfield
micrograph
platelet
wt
mous
taken
immedi
min
incub
blood
ngml
lp
prior
lp
applic
platelet
aggreg
platelet
absent
platelet
discoid
shape
left
panel
minut
incub
salin
platelet
morpholog
chang
top
panel
wherea
larg
aggreg
irregularlyshap
platelet
observ
incub
lp
bottom
panel
inset
show
platelet
pseudopodia
bar
repres
mm
similar
result
observ
blood
two
addit
anim
n
domain
contain
adaptor
induc
interferonb
trif
mediat
depend
independ
pathway
respect
lp
activ
trif
pathway
import
mediat
intracellular
signal
acut
effect
lp
platelet
leukocyt
activ
like
mediat
activ
platelet
posit
leukocyt
antigen
observ
blood
mice
furthermor
leukocyt
antigen
express
platelet
reduc
inhibit
trifdepend
pathway
alon
combin
signal
pathway
may
potenti
molecular
target
inhibit
infectioninflamm
induc
interact
among
form
element
blood
singl
sentinel
dose
inject
lp
use
studi
shorten
platelet
halflif
increas
platelet
product
without
increas
cytokin
product
within
hour
stimul
although
vivo
interact
plateletand
leukocyteaggreg
vascular
wall
could
stimul
exacerb
proinflammatori
immun
respons
halflif
cell
aggreg
known
signific
find
present
vivo
studi
leukocyt
sustain
retain
platelet
antigen
seven
day
vivo
inject
lp
time
point
correspond
turnov
platelet
pool
consist
observ
chang
platelet
halflif
increas
platelet
turnov
depend
concentr
agonist
ie
lp
activ
quantif
dualposit
event
usual
consid
studi
cellular
mv
quantif
lp
stimul
result
present
studi
therefor
suggest
plateletleukocyt
antigen
could
use
addit
biomark
cellular
activ
diagnost
prognost
purpos
set
subclin
asymptomat
exposur
infect
agent
monocyt
show
greatest
express
platelet
antigen
follow
lp
inject
sinc
monocyt
consid
primari
leukocyt
cell
involv
develop
atherosclerot
lesion
present
result
provid
insight
mechan
link
low
moder
level
infect
progress
cardiovascular
diseas
knowledg
result
present
studi
repres
first
examin
timedepend
chang
product
mv
exchang
cellspecif
antigen
cell
deriv
whole
blood
incub
lp
dilut
blood
addit
lp
ng
mgml
increas
number
mv
platelet
posit
tissu
factor
four
hour
incub
blood
dilut
unlik
present
studi
cellcel
interact
like
attenu
evalu
perform
rel
interact
leukocyt
could
indirectli
affect
platelet
activ
product
cytokin
unexpectedli
ps
express
platelet
leukocyt
increas
significantli
acut
exposur
lp
ps
express
inner
leaflet
plasma
membran
rapidli
invert
outer
surfac
follow
activ
stimuli
exposur
ps
outer
membran
surfac
also
occur
releas
mv
result
present
studi
consist
report
product
mv
accompani
ps
express
cell
origin
might
restrict
portion
membran
undergo
mv
bleb
within
one
hour
exposur
whole
blood
concentr
lp
threshold
effect
cytokin
product
vivo
platelet
becom
posit
leukocyt
antigen
plateletleukocyt
interact
requir
signal
dual
antigen
posit
platelet
observ
blood
deriv
wild
type
mice
furthermor
peptid
inhibitor
signal
molecul
block
interact
event
occur
within
hour
initi
exposur
lp
addit
effect
lp
stimul
sustain
least
day
past
initi
lp
exposur
leukocyt
express
platelet
antigen
time
point
collect
result
identifi
acut
rapid
signal
mechan
sentinelgrad
acut
infect
alter
blood
hemostasi
sustain
leukocyt
activ
may
contribut
progress
cardiovascular
diseas
